Upcoming ASCO abstracts

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week or so. They include updates on Brigatinib (2), HSP90 inhibitors combined with Crizotinib, Alectinib, brain metastases and ALK, and Lorlatinib.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, lorlatinib - Lorbrena by Pfizer, Lung cancer. Bookmark the permalink.

Leave a Reply